BACKGROUND: Several anti-inflammatory biologic medications are available in the United States for the treatment of moderate-to-severe rheumatoid arthritis, moderate-to-severe psoriasis, psoriatic arthritis, or ankylosing spondylitis. The tumor necrosis factor (TNF) blockers etanercept, adalimumab, and infliximab are approved for use in adults with any of these conditions, but predicting the annual costs of TNF-blocker treatment is complex due to differences in dosing schedules, treatment gaps, switching between TNF blockers, and dose escalation over time.
• The tumor necrosis factor (TNF) blockers etanercept, adalimumab, and infliximab have been approved in the United States for use in adults with moderate-to-severe rheumatoid arthritis, moderate-to-severe plaque psoriasis, psoriatic arthritis, or ankylosing spondylitis.
• Previous budget impact models compared the cost per treated patient for etanercept, adalimumab, or infliximab and determined that etanercept had the lowest cost to the payer; infliximab had the highest cost, and adalimumab had a similar or higher cost than etanercept.
• However, most of those analyses only included patients with rheumatoid arthritis; the 2 analyses that included all 4 conditions required different analysis periods for each condition because the TNF blockers were approved for different conditions at different times.
What is already known about this subject
• This study included patients with any of the 4 conditions for which etanercept, adalimumab, and infliximab are approved in adults, and it used data from the same time period for every condition to provide the most accurate representation of annual cost per treated patient for a health plan.
• Across all conditions combined, the annual TNF-blocker cost per treated patient was lowest for etanercept ($17,676), followed by adalimumab ($19,272) , and then infliximab ($24,273). The same pattern was seen among the 11,210 patients who newly started TNF-blocker treatment ($17,270, $17,959, and $21,482, respectively) and the 18,897 patients who were continuing ongoing TNFblocker treatment ($18,203, $20,453 , and $25,468, respectively). • For the analyses by condition, the annual cost of TNF blockers per treated patient was 26% to 72% greater for infliximab than for etanercept in each condition or combination and 3% to 31% greater for adalimumab than for etanercept in rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis and the combinations of conditions. Among patients with psoriasis, the cost per treated patient was 6% lower for adalimumab than for etanercept.
every other week in adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis; patients with plaque psoriasis receive an initial loading dose of 80 mg, followed by 40 mg every other week starting 1 week after the loading dose. 6 Infliximab is administered intravenously with a weight-based dose; there is an initial dose of 3 milligrams per kilogram (mg/ kg; rheumatoid arthritis) or 5 mg/kg (other conditions) at 0, 2, and 6 weeks, and then every 8 weeks thereafter (every 6 weeks in patients with ankylosing spondylitis). 7 Over time, dose escalation or more frequent administration may occur with adalimumab and infliximab, 4, [8] [9] [10] [11] [12] as is allowed in their prescribing information, 6, 7 but these dose escalations do not always improve outcomes. 13 The prescribing information for adalimumab notes that more frequent administration (once weekly) may be required in some patients with rheumatoid arthritis not receiving concomitant methotrexate, 6 and the prescribing information for infliximab includes recommendations to escalate the dose up to 10 mg/kg or decrease the dosing interval to 4 weeks as needed in patients with rheumatoid arthritis. 7 Conversely, the prescribing information for etanercept does not include recommendations for dose escalation; the recommended dose is 50 mg per week throughout treatment, except in patients with psoriasis (100 mg per week for the first 3 months, followed by a lower dose of 50 mg per week thereafter).
Along with changes in dosing, patients may discontinue, suboptimally adhere to, or switch therapies, which can also influence the costs of TNF-blocker therapy. When planning or measuring the impact of an initial therapy choice, formulary managers consider the impact of treatment changes as accountable to the index therapy. If the cheapest therapy is also the least effective or tolerable, the lower costs of initial therapy will be offset by patients switching to more expensive therapies.
This study used a nationwide managed care population to describe the annual TNF-blocker costs per treated adult patient who received etanercept, adalimumab, or infliximab and had rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, or a combination of 2 or more of these conditions. To provide an estimate of the cost of TNF-blocker treatment on a per-patient basis, real-world drug utilization, costs of the index and subsequent TNF blockers (among patients who switched treatments in the first year after the index date), and administration costs for these TNF blockers were included in this analysis.
■■ Methods Objective
The objective of this analysis was to estimate the annual cost per patient from the payer perspective for etanercept, adalimumab, or infliximab in adults with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. A retrospective analysis of a nationwide claims database was selected F ormulary decision makers within managed care organizations in the United States have a growing range of choices for anti-inflammatory biologic treatment. The wider range of choices introduces complexity with respect to approved indications and to variations in dosing schedules and method of administration by drug and indication. Combined with the influence of gaps in therapy, 1 nonpersistence, 2 and switching between agents within a given class, 3 it is difficult for pharmacy and therapeutics committees to determine the true annual economic impact of starting patients on a particular anti-inflammatory biologic.
Tumor necrosis factor (TNF) blockers are the most commonly used anti-inflammatory biologic treatments in the United States, and etanercept (ENBREL, Amgen Inc., Thousand Oaks, CA), adalimumab (HUMIRA, Abbott Laboratories, North Chicago, IL), and infliximab (REMICADE, Centocor Ortho Biotech Inc, Malvern, PA) are the most commonly used TNF blockers. Each has been approved for use in adults with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, or active ankylosing spondylitis. Etanercept and adalimumab are approved for use in adults with chronic, moderate-to-severe plaque psoriasis, and infliximab is approved for use in adults with severe plaque psoriasis when other systemic therapies are medically less appropriate. The most recent U.S. Food and Drug Administration (FDA) approval for any of these conditions was obtained in January 2008 for use of adalimumab in psoriasis. Each TNF blocker also has other indications in children and adults, such as Crohn's disease or juvenile idiopathic arthritis, that are not shared by all 3 products.
The effects of actual dosing, rather than recommended dosing, also need to be taken into consideration when estimating the cost to the payer for TNF-blocker treatment. 4 Etanercept is administered subcutaneously; the recommended dose is 50 milligrams (mg) once weekly in adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. 5 For adults with psoriasis, the recommended dose is 50 mg twice weekly for 3 months and then once weekly. 5 Adalimumab is administered subcutaneously; the recommended dose is 40 mg
• When patients switched to another TNF blocker in the first year, these costs were attributed to the index TNF blocker to account for treatment switches and to reflect a real-world estimate of the total TNF-blocker cost. An important distinction of this study is that it examined these nonindex costs within the total cost as well as separately from the index costs. A similar percentage (between 9% and 11%) of patients in each group switched to another TNF blocker or biologic. The cost of nonindex TNF blockers accounted for 16.8%, 13.4%, and 6.9% of the total annual cost of etanercept, adalimumab, and infliximab, respectively.
What this study adds (continued)
as the study design that would provide the most reliable and applicable estimates of annual utilization for a managed care population in a real-world setting.
Data Source
The Only health plans that submit data for all members are included in the database, ensuring complete data capture and representative samples. Data contributions are also subjected to a series of quality checks to ensure a standardized format and to minimize error rates.
Cohort Selection
Adults (18 to 64 years of age) were analyzed if they had at least 1 claim for etanercept, adalimumab, or infliximab between February 1, 2008 (the first month after the most recent FDA approval for the conditions studied) and July 5, 2010. The index date was the date of their first TNF-blocker (index TNFblocker) claim during the study period after at least 180 days of continuous enrollment in the managed care plan. Patients were required to be continuously enrolled in the managed care plan from at least 180 days before the index date (the preindex period) through at least 360 days after the index date (the follow-up period). Patients were considered to be either "new" patients (those that did not have a claim for the index TNF blocker in the pre index period) or "continuing" patients (those that did).
Patients were required to have a diagnosis (ICD-9-CM code) in the pre-index period for rheumatoid arthritis (714.0x), psoriasis (696.1), psoriatic arthritis (696.0), or ankylosing spondylitis (720.0). Patients were excluded if they had a diagnosis (ICD-9-CM code) in the pre-index period for juvenile idiopathic arthritis (714.3x), Crohn's disease (555.x), or ulcerative colitis (556.x) because these indications are not shared by all 3 of the index TNF blockers.
Consistent with Health Insurance Portability and Accountability Act (HIPAA) requirements, identifying information was removed from patient records to maintain confidentiality; thus, approval of an investigational review board was not required. Data cleaning was performed to ensure valid dispensed amounts and days supply data. Multiple claims on the same day were aggregated to a single claim. Claims with a zero or negative allowed amount were then deleted. If a patient's index claim was deleted, the patient was dropped from the analysis. Otherwise, the consolidated claim record was retained, and the quantity value was recorded as the sum of the same-day quantity values. For all medications, quantities were rounded to the nearest whole number (i.e., including the number of utilized prefilled syringes). After these steps, if the calculated weekly dose exceeded twice the maximum recommended dose across the 4 conditions (200 mg per week of etanercept, 80 mg per week of adalimumab, or 2,000 mg per infusion of infliximab [2 × 10 mg/kg × 100 kg]), the patient was dropped from the analysis.
Cost Analyses
Methods for cost analyses were determined a priori. Treatment effects were not evaluated, and comparative statistical tests were neither planned nor conducted. Actual allowed amounts on claims can vary between payers based on individualized contracting tiers and rebates. However, the intent of this analysis was to standardize the cost perspective across plan contributors and show the potential effect on a plan with a single negotiated price per drug/service in its benefit plan, rather than reflecting the costs paid by multiple payers after their independent negotiations for discounts and rebates. Thus, wholesale acquisition costs were used because they are standardized publicly available values. Similarly, Medicare Physician Fee Schedules provide publicly available values for cost, and individual plans can negotiate rates with individual providers.
To estimate the budget impact in current terms, April 2012 unit wholesale acquisition costs 14 were used as follows: etanercept 50 mg, $483.66; adalimumab 40 mg, $958.20; infliximab 100 mg, $744.92. Administration costs used the April 2012 update to the Medicare Physician Fee Schedule 15 as follows: $24.17 for the first in-office administration of subcutaneous etanercept or adalimumab for new patients and $0 for subsequent injections, which were assumed to be self-administered; and $169.16 ($138.53 for the first hour and $30.63 for the second hour) for each intravenous administration of infliximab. The assumption that intravenous administration of infliximab required 2 hours was validated against the distribution of administration times from CPT-4 codes in the LifeLink data (80.2% of infliximab patient days were associated with the CPT codes 96413/96415).
Net cost was estimated to be $473.51 for 50 mg of etanercept, $939.57 for 40 mg of adalimumab, and $739.89 for 100 mg of infliximab, based on calculations that added the dispensing fee ($2.50 for each subcutaneous injection) and subtracted the copayment or coinsurance ($50 per prescription for etanercept or adalimumab and $25 per infusion for infliximab 16 ), each of which was determined from the average quantity of each medication used per prescription or infusion. The average quantity of each medication used (in mg) per prescription or infusion was based on the total quantity dispensed summed across all pharmacy and medical claims, divided by the total number of prescriptions or infusions. The calculated values were etanercept 234 mg per prescription, adalimumab 102 mg per prescription, and infliximab 497 mg per infusion.
If a patient switched to 1 of the other 2 TNF blockers in the first year after the index date, costs of the subsequent treatments were attributed to the index TNF blocker to account for treatment switches and to reflect a real-world estimate of the annual cost of TNF-blocker treatment. Costs of medications other than the 3 TNF blockers were not included in this analysis. Patients were considered to be persistent to the index TNF blocker treatment if they had no treatment gaps of ≥ 45 days after the expected duration of supply per dose (7 days per 50 mg syringe of etanercept, 14 days per 40 mg syringe of adalimumab, and 8 weeks for infliximab). Patients were considered to have restarted treatment if they had a treatment gap of ≥ 45 days and then restarted the index TNF blocker. Patients were considered to have stopped treatment if they were not persistent, and they neither restarted nor switched treatment.
The per-patient cost was calculated as the total TNF-blocker expenditures in the first year after the index date for all patients combined, divided by the number of patients for that index treatment. In addition, cost per treated patient was determined separately (a) for each index TNF blocker, (b) for each condition, and (c) for new patients and continuing patients.
■■ Results Patient Demographics
A total of 30,107 patients satisfied the study criteria and were included in the analysis. A patient selection flowchart is provided in Figure 1 . The most common reasons patients who had received 1 of the TNF blockers during the study period were excluded from the analysis was that they did not meet the criterion for minimum continuous enrollment (i.e., they were not continuously enrolled in the plan from 6 months before through 12 months after the index date) or they did not have one of the required diagnoses in the pre-index period.
The most commonly used TNF blocker was etanercept (15,488 patients; 51.4%), followed by adalimumab (8, 959 patients; 29.8%) and infliximab (5,660 patients; 18.8%). Baseline characteristics of the study population are summarized by index TNF blocker in Table 1 . The majority of patients were female (etanercept 59.9%, adalimumab 62.5%, infliximab 67.6%); the majority had rheumatoid arthritis alone (50.1%, 54.0%, 65.2%); and the physician visit prior to the index claim was most commonly to a rheumatologist (40.7%, 42.1%, 62.2%). Approximately 2 in 3 patients overall were continuing their index TNF-blocker treatment at the time of the index TNF-blocker claim, including 66.0%, 52.6%, and 70.0% of patients in the etanercept, adalimumab, and infliximab groups, respectively. The payer type was similar across index TNF blockers, and most patients were insured through a commercial plan (86.0%) or were self-insured (10.0%), usually through a preferred provider (66.8%) or HMO (15.4%) plan. There were no meaningful differences between index TNF blockers regarding other baseline characteristics (plan type, geographic region). 
Total TNF-Blocker Cost
Across all indications, the annual TNF-blocker cost per treated patient was lowest for etanercept, followed by adalimumab and then infliximab. For all 30,107 patients combined (Figure 2A Annual cost per treated patient is presented by condition for all patients combined in Figure 2A , for new patients in Figure 2B , and for continuing patients in Figure 2C . The same rank order for cost (etanercept < adalimumab < infliximab) was seen for patients with rheumatoid arthritis, psoriatic arthritis, Total annual TNF-blocker cost per treated patient included both the cost of the index TNF blocker and the cost of nonindex TNF blockers (Table 2) . Overall, the annual cost per treated patient of nonindex TNF-blocker treatment was $2,991 of $17,767 (16.8%) for etanercept, $2,573 of $19,272 (13.4%) for adalimumab, and $1,664 of $24,273 (6.9%) for infliximab. A similar trend, with the greatest contribution of nonindex TNF-blocker costs to the total cost in the etanercept group, followed by the adalimumab and infliximab groups, was seen for each of the individual conditions and most combinations of conditions. After removing these costs, the annual cost per treated patient that was attributable to the index TNF blocker followed the same rank order as the total costs (etanercept < adalimumab < infliximab) for each condition and combination of conditions, except psoriasis alone (adalimumab < etanercept < infliximab).
Costs of Tumor Necrosis Factor Blockers Per Treated Patient Using Real-World Drug Data in a Managed Care Population

■■ Discussion
Using real-world drug utilization data among patients who had 1 or more of 4 commonly treated inflammatory conditions, more patients received etanercept than adalimumab or infliximab, and etanercept had the lower cost per treated patient. Infliximab had the highest overall annual cost per treated patient (137% relative to etanercept), followed by adalimumab (108% relative to etanercept). Similar patterns for annual cost per treated patient for all conditions combined were seen among patients who were new to the index TNF blocker and those who were continuing treatment with the index TNF blocker.
This analysis included patients with any 1 of 4 conditions for which etanercept, adalimumab, and infliximab are each approved for use in the United States, including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and combinations of these conditions. This approach provided a comprehensive evaluation of the total cost per treated patient that a payer can expect when making formulary decisions, rather than just the cost associated with 1 of the approved indications (e.g., rheumatoid arthritis).
When the annual cost per treated patient was analyzed by condition, the same rank order of etanercept, followed by adalimumab and infliximab, was observed across all conditions except psoriasis. In patients with psoriasis alone, the cost of adalimumab was 6% lower than the cost of etanercept, but the relative cost of infliximab to etanercept (126%) was consistent with those of the other conditions. One explanation is that etanercept dosing recommendations for adults with psoriasis include a loading dose in the first 3 months, which would be ankylosing spondylitis, and combinations of the 4 conditions. For patients with these conditions, the annual cost of TNF blockers per treated patient was 3% to 31% greater for adalimumab than for etanercept and 26% to 72% greater for infliximab than for etanercept. For patients with psoriasis alone, the annual cost per treated patient was 6% lower for adalimumab than for etanercept and 26% greater for infliximab than for etanercept.
Contribution of Nonindex TNF-Blocker Costs
In the first year after the index claim, 75.3%, 70.0%, and 75.8% of patients in the etanercept, adalimumab, and infliximab groups, respectively, were either persistent to their index TNF-blocker treatment (etanercept 49.6%, adalimumab 51.2%, and infliximab 64.7%) or they had a ≥ 45-day gap in the index treatment and then restarted the same TNF blocker (etaner- 22, 23 the start dates varied by condition, according to when all 3 TNF blockers had been granted approval for that condition. However, the present analysis included both the most recent data that were available at the time of the analysis and greater follow-up among patients with psoriasis (the condition for which the most recent FDA approval was granted). Another key difference was that a patient was considered to be on new (or continuing) TNF-blocker treatment at the index date on the basis of a claim for that specific TNF blocker in the 6-month pre-index period, rather than a claim for any prior TNF blocker in the pre-index period. Lastly, cost estimates were based on cost per claim, rather than cost per injection or vial, and the average dose per claim was included in the estimate of net cost per unit. These differences in study design made it possible to estimate more accurately the real-world cost of index TNF-blocker treatment based on actual usage.
Limitations
The analysis was designed to provide a generalized estimate of TNF-blocker costs, so the drug acquisition costs did not include discounts, rebates, and other price concessions. Efficacy and outcomes were not analyzed, but they have been shown previously to be similar between TNF blockers. [24] [25] [26] [27] [28] [29] [30] [31] The model included an adjustment for the cost of copayment and dispensing fees and did not consider the cost to a plan that uses coinsurance. This approach, combined with the fact that all patients in the analysis were continuously enrolled in a managed care plan, may limit the generalizability of these results in patients who are not enrolled in managed care plans. However, because the objective of the analysis was to estimate the cost per treated patient from the payer's perspective in a managed care setting, the analysis was not intended to provide cost data for other populations.
The model included the cost of nonindex TNF-blocker treatment. As discussed above, this accounted for the contribution of switching therapies to the total cost. However, costs of medications other than the 3 TNF blockers were not included in this analysis. The percentage of patients who switched to another biologic was 1.5%, 3.0%, and 5.7% in the etanercept, adalimumab, and infliximab groups, respectively. Because of these differences in rates of switching to non-TNF biologics, inclusion of their costs likely would have increased the estimates of total cost per treated patient for adalimumab and infliximab as compared with etanercept. Conversely, we did not explicitly quantify the contribution of persistence and treatment gaps to the overall cost per treated patient in this analysis, and previous research suggests that higher persistence to infliximab may contribute to its higher costs as compared with etanercept and adalimumab. 32 More than half of the patients who received a TNF blocker during the study period were excluded from the analysis. Many expected to increase the relative cost of etanercept in the first year. This would help to explain why the total cost per treated patient among patients with psoriasis was approximately 7% lower for adalimumab than for etanercept among patients who were new to TNF-blocker treatment, and 5% lower among those who were continuing treatment, although the latter cohort could include patients who had received as little as 1 prior TNF blocker injection before the index date. The sample size of patients with psoriasis was much smaller than the sample of patients with rheumatoid arthritis, and thus the relative costs for psoriasis should be interpreted with this caveat. Although the analyses by condition provide interesting insights into the contribution of each to the total cost, the analyses for all conditions combined provide the most reliable and potentially the most relevant cost estimates for payers and formulary decisions. Thus, this analysis complements previous analyses that also reported that the cost of etanercept was the lowest of the TNF blockers among patients with rheumatoid arthritis. [17] [18] [19] [20] [21] In this analysis, estimates of total annual costs of TNFblocker treatment included the costs of both the index TNF blocker and the nonindex TNF blockers among patients who switched treatment in the first year after the index date. The intent was to provide a real-world estimate of the total annual cost of TNF-blocker treatment. Despite the fact that a similar percentage of patients in each treatment group switched biologic treatment (9% to 11% in each group), the contribution of the costs of these nonindex TNF blockers was 16.8%, 13.4%, and 6.9% of the total costs per patient in the etanercept, adalimumab, or infliximab groups, respectively. If the analysis had excluded these costs and included only the direct cost of the index TNF blocker, the rank order for TNF-blocker cost would have been the same, both overall and by condition, but the relative costs would have favored etanercept more.
Two previous analyses that used similar methods with claims from January 2005 to March 2009 also reported that etanercept had the lowest cost, followed by adalimumab and infliximab, among patients with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. 22, 23 The present analysis is different in a few important ways. Recognizing the importance of nonindex costs to the total cost, this analysis summarized the individual contributions of index and nonindex costs to the total. Examining these data separately allows managed care pharmacists to fully appreciate the important contribution of nonindex costs to total costs, as well as any differences between agents in these contributions. Another key distinction of this analysis was that it provided a more homogeneous, representative sample than the previous publications. It included data from August 2007 through June 2011, with index claims that occurred between February 2008 and July 2010. Because etanercept, adalimumab, and infliximab had each been approved for all 4 conditions prior to February 2008, this allowed the cost estimates to be based on the same time of these patients were excluded because they did not have the minimum required enrollment in the health plan from 6 months before the potential index date (during which other study eligibility criteria were evaluated, such as an ICD-9-CM code for 1 of the studied conditions) through 12 months after the potential index date (to allow evaluation of all TNF-blocker costs). Although the exclusion of these patients substantially reduced the sample size, it provided confirmation of the indicated condition near treatment initiation. However, the impact of excluding these patients on the cost estimates is unknown.
■■ Conclusions
Based on real-world drug utilization data in adult patients with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis, or some combination of these conditions, etanercept had a lower cost per treated patient than adalimumab or infliximab, except in patients with psoriasis alone. In these patients, adalimumab had a lower cost per treated patient than etanercept or infliximab. If all indications are grouped together, etanercept had the lowest cost per treated patient followed by adalimumab and then infliximab, a rank order that is seen regardless of whether the cost of nonindex TNF-blocker treatment is included in the total annual cost per treated patient for the index TNF blocker. These findings, when combined with the available evidence of the comparative efficacy and safety of TNF blockers in the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis, may be used by decision makers to support formulary decisions.
